Singapore: +65-31631880 | India: +91-40-42023318
  U.S / Canada Toll Free: +1-866-259-4781
  Kenya: +254-732-300719

          

Clinical Trial News

Ebola vaccine: Promising phase I trials

"The results for tolerability, safety, and the immune response to the vaccine candidate are very promising," explains Prof Marylyn Addo.

12-month data highlight the safety and efficacy of ab-interno canaloplasty in primary open-angle glaucoma

Ellex Medical Lasers Ltd is pleased to announce findings from a 12-month case series review of 228 patients with primary open-angle glaucoma (POAG) which show that ab-interno canaloplasty (ABiC)...

NightstaRx reports long-term benefits of gene therapy for inherited form of progressive blindness

NightstaRx Ltd, a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, today announced the publication from the University of Oxford of promising...

Massive failure to publish trial results exposes patients to risks without providing benefits for others

Although the publication of results of clinical trials carried out in the US within 12 months of their completion has been mandatory since 2007, an astoundingly high number of Phase III radiotherapy...

Scientists teaching machines to make clinical trials more successful

Scientists are teaching computers to figure out why people accept or decline invitations to participate in clinical trials.

Multiple myeloma: Phase 3 trial results for the oral proteasome inhibitor ixazomib published in the New England Journal of Medicine

Results from the TOURMALINE-MM1 Phase 3 clinical study, published in the New England Journal of Medicine, have shown that oral ixazomib capsules in combination with lenalidomide and dexamethasone...

COPD: Sunovion Pharmaceuticals Inc. announces positive results from two Phase 3 clinical studies evaluating SUN-101/eFlow

Sunovion Pharmaceuticals Inc. (Sunovion) has announced positive results from the Phase 3 clinical trial program for SUN-101 (glycopyrrolate), a nebulized long-acting muscarinic antagonist (LAMA)...

Alizé Pharma reports positive results from its Phase II clinical trial of AZP-531 in Prader-Willi Syndrome

Results from the randomized, double blind and placebo-controlled Phase II trial show significant improvements in hyperphagia-related behavior, a key therapeutic objective in Prader-Willi Syndrome.



James Lind Institute Newsletter
James Lind Institute Linkedin
James Lind Institute RSS
James Lind Institute Email Update
James Lind Institute Blog
James Lind Institute Facebook